0001667699-25-000002.txt : 20250717 0001667699-25-000002.hdr.sgml : 20250717 20250717164541 ACCESSION NUMBER: 0001667699-25-000002 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20250717 DATE AS OF CHANGE: 20250717 EFFECTIVENESS DATE: 20250717 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Renibus Therapeutics, Inc. CENTRAL INDEX KEY: 0001667699 ORGANIZATION NAME: EIN: 810872431 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-483766 FILM NUMBER: 251131144 BUSINESS ADDRESS: STREET 1: 181 GRAND AVE., SUITE 225 CITY: SOUTHLAKE STATE: TX ZIP: 76092 BUSINESS PHONE: 386-527-1071 MAIL ADDRESS: STREET 1: 181 GRAND AVE., SUITE 225 CITY: SOUTHLAKE STATE: TX ZIP: 76092 D/A 1 primary_doc.xml X0708 D/A LIVE 0001667699 Renibus Therapeutics, Inc. 181 GRAND AVE., SUITE 225 SOUTHLAKE TX TEXAS 76092 386-527-1071 DELAWARE None None Corporation true Carlos Guillem 181 Grand Ave., Suite 225 Southlake TX TEXAS 76092 Director D. Jeffrey Keyser 181 Grand Ave., Suite 225 Southlake TX TEXAS 76092 Executive Officer Director Henrik Rasmussen 181 Grand Ave., Suite 225 Southlake TX TEXAS 76092 Director Bhupinder Singh 181 Grand Ave., Suite 225 Southlake TX TEXAS 76092 Executive Officer Director Jamie Donadio 181 Grand Ave., Suite 225 Southlake TX TEXAS 76092 Executive Officer Pharmaceuticals Decline to Disclose 06b true 0001567619-23-007234 2023-05-25 true true true true false 0 Salem Partners LLC 43363 None None 11111 Santa Monica Blvd., Ste. 2250 Los Angeles CA CALIFORNIA 90025 GA GEORGIA TX TEXAS false 110895239 110895239 0 Amounts listed include amounts from certain converting SAFEs, which may have been previously reported on Form D, and certain warrants (see Item 15). The SAFEs converted into Series B-1 Preferred Stock at the initial closing of the transaction. false 59 0 148332 true Issuer paid placement agent cash fee of 1% of aggregate amount of proceeds from sale of Series B Preferred from 06/06/2025 to 06/17/2025 and issued placement agent warrants to purchase up to 96,971 shares of Common Stock (exercise price per share, $1.61). 0 false Renibus Therapeutics, Inc. /s/ D. Jeffrey Keyser D. Jeffrey Keyser Chief Executive Officer 2025-07-17